ESSENTIAL PHOSPHOLIPIDS IN THE TREATMENT OF HEPATIC DISORDERS


DOI: https://dx.doi.org/10.18565/pharmateca.2018.s3.40-43

S.A. Bulgakov

Russian National Research Medical University n.a. N.I. Pirogov, Moscow, Russia
The article presents main ideas about the therapeutic possibilities of drugs – hepatoprotectors, created on the basis of essential phospholipids (EPLs), in the treatment of common hepatic disorders. The etiopathogenetic mechanisms of non-alcoholic fatty liver disease, metabolic syndrome, and alcoholic liver disease are considered. Disputable data on various views on the possibility of using EPLs in the treatment of these diseases are given. It is concluded that the use of EPLs in the treatment of hepatic disorders is reasonable.

About the Autors


Corresponding author: S.A. Bulgakov – MD, Prof., Leading Scientist at the SRI of Translational Medicine RNRMU n.a. N.I. Pirogov, Moscow, Russia; e-mail: av22956@akado.ru; ORCID: https://orcid.org/0000-0002-9004-9400


Similar Articles


Бионика Медиа